| Previous close | 3.3500 |
| Open | 3.0000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 125.00 |
| Expiry date | 2024-05-24 |
| Day's range | 3.0000 - 3.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Yahoo FinanceEli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
BloombergThe Ozempic Effect: How a Weight Loss Wonder Drug Gobbled Up an Entire Economy
(Bloomberg) -- There is no escaping Ozempic and Wegovy. The diabetes and obesity drugs are a global phenomenon. They’ve won over the rich and famous, generated billions in sales and blown open a new market for weight loss drugs, which Goldman Sachs estimates will reach $100 billion a year by 2030.Most Read from BloombergTesla Axes Supercharger Team in Blow to Broader EV MarketAmazon Reports Strong Cloud Unit Sales on Rising AI DemandPot Stocks Surge on Report DEA Set to Reclassify MarijuanaHSBC
- Reuters
UPDATE 1-Novo Nordisk owner to invest $200 million in quantum computing startups
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, said on Wednesday it planned to invest around $200 million in quantum computing startups. The company, the investment arm of the Novo Nordisk Foundation, has 77% of voting shares in Novo Nordisk, which is known for producing blockbuster obesity drug Wegovy and diabetes treatment Ozempic. Academics and industry analysts say quantum computing may prove to be among the most transformational technological developments of the 21st century.
